WCG Announces the Formation of WCG IRB and Launch of WCG IRB Connexus
WCG has announced the unification of its five IRBs—Western IRB (WIRB), Copernicus Group IRB (CGIRB), Midlands IRB (MLIRB), New England IRB (NEIRB), and Aspire IRB—into the single WCG IRB brand. Since 2012, the organization has assembled and integrated an array of IRBs, now synthesized into a single IRB. WCG IRB clients will experience a singular, unified process and submission platform.
This transformation includes the launch of a new technology, WCG IRB Connexus, which supports their clients’ ethical review submissions and management.
“By deploying adaptive technology, the new WCG IRB Connexus supports our commitment to continuous improvement of our processes by raising the bar on transparency and compliance,” said David Forster, WCG’s Chief Compliance Officer. “And that’s our goal—to improve the submission process, eliminate and reduce errors."
Details of these changes are being announced this week through the WCG IRB website.
Read more in the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
